PRP and Metaplasia in repaired tendon
Kamal Seyyed–Forootan, Hamid Karimi, Ahmad–Reza Dayani
Plastic & Reconstructive Surgery, Iran University of Medical Sciences, Tehran, Iran

1. Introduction

Achilles is the largest tendon of the body and has an important role in stability of body, posture and walking. Trauma to this tendon is very common especially in Atletists. The treatment modalities for tendon rupture are diverse.

These treatments are not complete and have side effects and sometimes is with pain after the treatment[1]. One of the new modalities is PRP injection in the repair site.

It is shown that PRP can help in healing process of soft and hard tissues and has been used in Orthopedics, Dentistry, Dermatology, Plastic and Maxillofacial surgeries[2]. Some of the studies showed the mitogenic effects of PRP and have emphesised on the role of the growth factors in PRP[3].

Adhesion is one the problems after tendon repair and needs early movement of tendon, although early movement may induce rupture of the tendon[4,5]. To overcome these effects some authors suggest using growth factors to strengthen the repair site and early start of tendon movement. We know that PRP has TGF and VEGF and can induce chemotaxis, fibroblast proliferation, collagen synthesis, cell proliferation and increase of angiogenesis.

PRP is an autologus, non expensive and simple tissue that has regeneration power, it has no allergic or infectious side effects and it is shown that PRP would remain for one week in the repair site, so it seems that one dose of injection would be enough for tendon repair[6–15].

2. Materials and methods

The study was performed on 20 Vaster albino male rats, weighting 200–250 g and age about 2 months. The rats were kept in separate cages with 12 h day and night cycle and temperature of 24–28 degree of centigrade and enough food and water. The animals were kept under Helsinki protocol. All of the surgeries were done by the same surgeon. Rats were anesthetized with Ketamin 15 mg/kg and Xilocaie 5 mg/kg. Ceftriaxone 60 mg/kg IM were injected into the rats before surgery. 2.5 cc of Blood were taken from the rats and...
Centrifuged and the PRP was isolated with pipette. Incision were made over distal third of Achilles tendon and tendons dissected and cut in distal third and then repaired with Vicryl 4/0 (Figure 1). In first group no other treatment was done but in second group 0.5 cc of PRP were injected in the repair site then skin closed with nylon 4/0. Splint applied over the legs and rats were kept in the cages and were free to move. The rats were examined every other day by a physician. None of the rats died during the study.

No infection were seen during the study.

Figure 1. Cutting of the Achilles tendon.

After 28 days all of the rats executed with CO₂ gas without any pain. And the tendons were removed with calcaneous bone. Seben tendons in each group were selected randomly and sent for tensilometry (Figure 2). The force that needed to rupture the tendons were measured in newton.

Five mm by 5 mm of the tendons in the repair site were sent for pathologic exam. The pathologist were blinded about the two groups. The samples were colored with hematoxilin and eosin and studied for the number of fibroblasts, collagenes and their orientation and vascularization. Photographies were taken from the samples.

The results were expressed as mean±Standard deviation and analyzed with SPSS 16 software, P<0.05 were considered significant. For analysing ANOVA test, Mann–Whitney, Wilcoxon, Tukey and Dunnet test were used.

Figure 2. Tendon samples for tensilometry.

3. Results

All of the rats were alive after 28 days. The mean force that was needed for tendon rupture were 47 newtons in control group and 57 newtons in PRP group (P=0.193). In the control group in 2 tendons, rupture happened with force of 40 newtons. But none of the tendon in PRP group rutured with forces less than 40 newtons. The maximum force in control group was 70 newtons and in PRP group 82 newtons. In 28% of control group rupture happened with forces less than 40 newtons. And in PRP group, 14% ruptured with forces more

| Table 1 | Comparison of forces that need to rupture the tendons after 4 weeks (P=0.193). |
|---|---|---|---|---|---|---|---|---|---|
| Mean | Total | C7 | C6 | C5 | C4 | C3 | C2 | C1 | Control group |
| 47 | 7 cases | 34 | 43 | 47 | 57 | 43 | 35 | 70 | Force (Newton) |
| Mean | Total | P7 | P6 | P5 | P4 | P3 | P2 | P1 | PRP group |
| 57 | 7 Cases | 43 | 57 | 63 | 82 | 43 | 45 | 67 | Force (Newton) |

| Table 2 | Comparison of mean of forces that need to rupture the tendons between the two groups (P=0.193). |
| Difference (%) | Control group(Newton) | PRP group(Newton) |
| 21% | 47 | 57 | Mean |

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Metaplasia</th>
<th>Neo–vascularization</th>
<th>Number of Fibroblasts</th>
<th>Collagen orientation</th>
<th>Collagen</th>
<th>Chronic phase inflammatory cells</th>
<th>Acute phase inflammatory cells</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>−</td>
<td>3+</td>
<td>3+</td>
<td>1+</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>C1</td>
<td></td>
</tr>
<tr>
<td>−</td>
<td>2+</td>
<td>2+</td>
<td>1+</td>
<td>2+</td>
<td>2+</td>
<td>0</td>
<td>C2</td>
<td></td>
</tr>
<tr>
<td>−</td>
<td>1+</td>
<td>2+</td>
<td>1+</td>
<td>1+</td>
<td>1+</td>
<td>0</td>
<td>C3</td>
<td></td>
</tr>
<tr>
<td>−</td>
<td>3+</td>
<td>2+</td>
<td>1+</td>
<td>1+</td>
<td>2+</td>
<td>0</td>
<td>P1</td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>3+</td>
<td>3+</td>
<td>1+</td>
<td>2+</td>
<td>2+</td>
<td>0</td>
<td>P2</td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>3+</td>
<td>3+</td>
<td>1+</td>
<td>2+</td>
<td>1+</td>
<td>0</td>
<td>P3</td>
<td></td>
</tr>
</tbody>
</table>
than 80 newtons (Table 1 & 2).

On average the force that needed for rupture of tendons in PRP group were 20% more than the control group (Figure 3). The samples were examined for number of acute and chronic phase inflammatory cells, fibroblast, fibrosis, collagen fibers orientation, vascularization and metaplasia (Figure 4 & 5). Acute phase inflammatory cells were not found in the samples.

![Figure 3](image1.png)

**Figure 3.** Comparison of the tensile strength between the two groups.

![Figure 4](image2.png)

**Figure 4.** Neo-vascularization.

![Figure 5](image3.png)

**Figure 5.** Collagen fibrils and orientation.

Fibroblast orientation were not different in both groups. Number of fibroblasts were shown in table 3. The difference in the two groups were not significant. In PRP group two cases of Metaplasia were seen, cartilage Metaplasia was seen in two samples (Figure 6 & 7).

![Figure 6](image4.png)

**Figure 6.** Cartilage metaplasia.

![Figure 7](image5.png)

**Figure 7.** Cartilage metaplasia after using PRP in tendon.

### 4. Discussion

Musculoskeletal injuries are the most common cause of severe long-term pain and physical disability, and affect hundreds of millions of people around the world. Therapeutic approaches to tendon healing do not always result in a satisfactory anatomical and functional repair, and healed tendon is often characterized by functional impairment and high risk of reinjury. Recently, mesenchymal stem cells (MSCs) and platelet rich plasma (PRP) have been proposed as novel therapeutic treatments to improve the tendon repair process. MSCs are multipotent, easy to culture and being originated from adult donors do not pose ethical issues. To date, autologous MSCs have been investigated mainly in the treatment of large bone defects, cardiovascular diseases, osteogenesis imperfecta and orthopaedic injuries both in human and veterinary medicine[4].

One of the most popular methods used to biologically enhance healing in the fields of hand surgery, orthopaedic surgery and sports medicine includes the use of autologous blood products, namely, platelet rich plasma (PRP). PRP is an autologous concentration of human platelets to supraphysiologic levels. At baseline levels platelets function as a natural reservoir for growth factors including platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor—beta 1 (TGF—β 1), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF), hepatocyte growth factor (HGF), and insulin—like growth factor (IGF—I). Platelet—rich plasma (PRP) is derived
from centrifuging whole blood, has a platelet concentration higher than that of the whole blood, is a part of the cellular component of plasma that settles after centrifugation[3], and now a days is commonly used in orthopaedic practice to augment healing in sports–related injuries of skeletal muscle, tendons, and ligaments. Despite its pervasive use, the clinical efficacy of PRP therapy and varying mechanisms of action have yet to be established. Basic science research has revealed that PRP exerts effects through many downstream events secondary to release of growth factors and other bioactive factors from its alpha granules. These effects may vary depending on the location of injury and the concentration of important growth factors involved in various soft tissue healing responses. Current findings in PRP basic science research, which have shed light on its proposed mechanisms of action, have opened doors for future areas of PRP research. We know that specific growth factors may play a crucial role in the healing process. There is abundant enthusiasm in the application of concentrated platelets, which release a supra–maximal quantity of these growth factors to stimulate recovery in injuries.

There is increasing interest in the sports medicine and athletic community about providing endogenous growth factors directly to the injury site using autologous blood products such as PRP, to potentially facilitate healing and earlier and faster return to sport after musculoskeletal injury[3].

Platelet rich plasma (PRP), the autologous plasma fraction with a platelet–rich cellular component, Due to its availability and low cost, has become an increasingly popular clinical tool as an alternative source of growth factors for various applications, for example tendon regeneration but with limited success in clinical trials[3]. Platelet–rich plasma (PRP) therapy aims to improve the process of tissue repair through local delivery of autologous bioactive agents to influence critical physiological mechanisms such as inflammation angiogenesis, or extracellular matrix synthesis. These biological properties have prompted the therapeutic administration of PRP in reconstructive and sports medicine. Given its biocompatibility and healing properties, percutaneous injections of PRP are also used in athletes to treat tendon and muscle injuries[30] and also for the treatment of ligament, cartilage injuries and early osteoarthritis[31], lateral epicondylitis, ligament and muscle strains, and tears of the rotator cuff anterior cruciate ligament, and Achilles tendon[16]. Platelet–rich plasma can be applied at the site of injury either during surgery or through an injection performed in the physician’s office. And many investigators are exploring the ways in which this therapy can be used in the clinical setting. However, there is little published clinical evidence that proves its efficacy in treating the multitude of injuries/disorders that are thought to benefit from PRP[16]. The potential risks involved with PRP are fortunately very low. However, benefits remain unproven to date[3]. PRP use in tendon and ligament injuries has several potential advantages, including faster recovery and, possibly, a reduction in recurrence, with no adverse reactions described[17]. Some results indicate that PRP exerts anti-inflammatory effects on injured tendons through HGF. This study provides basic scientific evidence to support the use of PRP to treat injured tendons because PRP can reduce inflammation and thereby reduce the associated pain caused by high levels of PGE2[18] and reduction in pain may facilitate early movement of tendon and limb.

In 2010, Zhang et al reported that PRP treatment of injured tendons is “safe” as it promotes TSC differentiation into tenocytes rather than nontenocytes, which would adverse effects on the structure and function of healing tendons by formation of nontendinous tissues. Moreover, they suggest that PRP treatment can enhance tenocytes to proliferate quickly and produce abundant collagen to repair injured tendons[19].

PRP secretes many growth factors, including transforming growth factor beta1 (TGF–beta1), platelet derived growth factor, vascular endothelial growth factor, insulin–like growth factor 1, and so on, which can induce cell proliferation, chemotaxis, and collagen synthesis for wound healing. It is shown that PRP can facilitate rabbit’s tendons healing and significantly improve the healing quality[20]. PRP is also used in conjunction with other product such as: TCA[21], MSCs [22], ASCs[23], fibrin matrix[24], TSC tendon stem cells[25], Leukocyte– and platelet–rich plasma[26]. The “Cascade” membrane a thin layer of autologous fibrine that is very rich in platelets and is obtained by high speed centrifugation of a small quantity of PRP[27].

The repair process of tendon injuries, is slow and the quality of the repair tissue is often inferior to the original tendon tissue, which frequently leads to re–injury. The relatively poor vascularization of tendons is one of the reasons. PRP, rich in growth factors, enhance the vascularization. The vascular endothelial growth factor, a powerful stimulator of angiogenesis, is abundantly present in PRP suggesting that enhancement of neovascularization might be one of the mechanisms. Bosch et al in 2011 shown that PRP induced significantly more neovascularization than the placebo treatment until at least 23 weeks after treatment, as detected by both Doppler ultrasonography and Factor VIII staining long–lasting effect[28] and it has Lyras et al also stated that The poor vascularity of tendons is a major factor in their limited healing capacity. Their study shown significantly more angiogenesis in the PRP group during the first two weeks of the healing process, i.e inflammatory and proliferative phase.

The number of the newly formed vessels in the PRP group were significantly reduced at 4 weeks compared to the controls (\(P<0.0001\)) meaning that the healing process was shortened. And concluded that PRP may accelerate the healing process and promote scar tissue of better histological quality[29]. Histologically it is seen that healing process in the tendons of PRP group is faster. In the first 2
weeks of healing, IGF–1 was found intracellularly in various type cells, whereas in the last 2 weeks of healing IGF–1 was detected mainly in tenocytes. Both cytoplasmic and nuclear expressions were present, whereas the larger amounts of immunoexpression were localized in both epitenon and endotenon. And it was concluded that PRP may improve tendon defect healing by overexpression of IGF–1[30].

In early phases of tendon healing processes, circulation–derived cells temporarily exist in the wounded area to initiate the healing process and decrease in number with time. In a study Kajikawa et al said that a delay of time-dependent decrease in circulation–derived cells could improve the healing of tendons. They injected PRP into the wounded area of the patellar tendon, and compared the effects on activation of circulation–derived cells and enhancement of tendon healing and concluded that locally injected PRP is useful as an activator of circulation–derived cells for enhancement of the initial tendon healing process[31]. The repair of subcutaneous tendon ruptures can be stimulated by a single application of one of several growth factors [e.g. platelet–derived growth factor (PDGF), transforming growth factor (TGF)–beta, insulin–like growth factor (IGF)–1, vascular endothelial growth factor (VEGF), bone morphogenetic proteins (BMPs) like growth differentiation factor (GDF)–5, –6, –7]. The response to these measures is dependent on the mechanical microenvironment. So far, almost all research has been limited to rodent models, mostly using the rat Achilles tendon[32].

PRP increases metabolic activity and seems to advance maturation of repair tissue over nontreated experimentally induced tendon lesions, which suggests that PRP might be beneficial in the treatment of clinical tendon injuries[33]. Also Mechanical stimulation improves the repair of ruptured tendons. Injection of PRP can also improve repair in several animal models. In a rat Achilles tendon transaction model, one postoperative injection resulted in increased strength after 4 weeks. Considering the short half–lives of factors released by platelets, this very late effect calls for an explanation that Platelets influence only the early phases of regeneration, but this allows mechanical stimulation to start driving neo–tendon development at an earlier time point[34].

Many commercial preparation systems for PRP therapy are available, but the optimal preparation remains unknown. Increasing numbers of clinical studies evaluating PRP have been reported and have provided both positive and negative evidence for its effectiveness. Well–designed, controlled studies are still lacking, but PRP may have a benefit for patients with tendinopathy that is refractory to other non–surgical treatments. Its use in tendon repair is currently not supported

Randomized, controlled studies with documentation of platelet, white blood cell, and growth factor concentration in the PRP preparation are necessary for future comparative research[35]. However, whatever is the mechanism of action of PRP, the result has to be a stengthen and strong tendon that would not rupture again. There are reports that an injection of PRP in sectioned rat Achilles tendon influences the early phase of tendon healing and results in an ultimately stronger mechanical resistance[36,37]. And in contrast other studies showed that a single injection of PRP appears not useful for Achilles tendon tears[38].

In this study we examined the result of using PRP and measured the force that are needed to re–rupture the newly repaired tendon. Our results showed that the tensile strength of tendons in PRP group are more but not significantly different. Also we examined the samples histologically to find any sign of remained or delayed healing process in the tendons. The results revealed that the healing process are complete after 4 weeks in both groups and there is not any delay in its process. The collagen fibers and their orientation are the same. The orientation of collagen fibers in the PRP group was better organized but not different significantly.

And interestingly the vascularization in the two groups were not different significantly. Therefore our result does not support using PRP as an adjuvant in treatment of tendon ruptures. PRP has not strengthened the tendon repair site and did not improve the mechanical properties of repaired tendon. More over accidental finding of two cases of metaplasia is a warning alert sign. Existence of Metaplasia in treatment site is a new finding (complication?) and varant further comprehensive studies in this kind of therapy.

PRP does not improve tendon rupture healing. It seems that all aspects of using PRP are not completely understood and further studies are still necessary to find its role in healing processes. Cartilage metaplasia, as far as we know, has not been reported yet in PRP treatment and may have some adverse effects on the results of tendon repair.

Conflict of interest statement

We declare that we have no conflict of interest.

References


Virechenko O, Aspenberg P. How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks? Interplay between early regeneration and mechanical stimulation; Acta Orthop 2006; 77(5): 806–812.


